NCT02266329View on ClinicalTrials.gov

Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

January 4, 2016

Primary Completion Date

May 31, 2023

Study Completion Date

September 30, 2023

Conditions
Posttraumatic HeadacheCombat DisordersPost Concussion SyndromeHeadacheMild Traumatic Brain InjuryPosttraumatic Migraine
Interventions
DRUG

prazosin hydrochloride

Prazosin as oral capsules titrated to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.

DRUG

placebo

Oral capsules of placebo identical in appearance to prazosin capsules titrated in the same manner as prazosin.

Trial Locations (1)

98108-1532

VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT02266329 - Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin | Biotech Hunter | Biotech Hunter